Safety of ADCs in MBC: Module

CME

Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 07, 2024

Expiration: February 06, 2025

Komal Jhaveri
Komal Jhaveri, MD, FACP

Activity

Progress
1 2
Course Completed

SG and T-DXd: Dosage and Administration Strategies

Both SG and T-DXd have dose reduction strategies to manage the associated AEs.2,3 Patients receiving SG should be monitored during the infusion and for 30 minutes after completion of the infusion. The dose can be reduced from 10 mg/kg on Days 1 and 8 of each cycle to 7.5 mg/kg and then to 5 mg/kg before treatment discontinuation if AEs persist without resolution. With T-DXd, the dose can be reduced from 5.4 mg/kg every 3 weeks to 4.4 mg/kg and then to 3.2 mg/kg before treatment discontinuation should further dose reduction be required. The lower dose levels of these agents can help improve tolerability.